Who are Nourianz's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lariam, Lariam, Trisoralen, Norgesic, Lexiscan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/istradefylline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nourianz — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nourianz (ISTRADEFYLLINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CYP3A4 Substrates. Area: Neuroscience.

marketed CYP3A4 Substrates Adenosine receptor A2a Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Nourianz (ISTRADEFYLLINE) — Kyowa Kirin. Nourianz works by blocking the adenosine receptor A2a, which helps to increase dopamine levels in the brain.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nourianz TARGET	ISTRADEFYLLINE	Kyowa Kirin	marketed	CYP3A4 Substrates	Adenosine receptor A2a	2019-01-01
Lariam	MEFLOQUINE HYDROCHLORIDE		marketed	Antimalarial	Adenosine receptor A2a	1989-01-01
Lariam	MEFLOQUINE		marketed	Antimalarial	Adenosine receptor A2a	1989-01-01
Trisoralen	TRIOXSALEN		marketed	Psoralen	Adenosine receptor A2a	1964-01-01
Norgesic	caffeine	Hikma	marketed	Central Nervous System Stimulant [EPC]	Adenosine receptor A2a	1948-01-01
Lexiscan	Lexiscan	Medical University of South Carolina	marketed		Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CYP3A4 Substrates class)

Kyowa Kirin · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nourianz — Competitive Intelligence Brief. https://druglandscape.com/ci/istradefylline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing